AAPL vs PFE: Which Is the Better Buy?
Side-by-side comparison of Apple Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-24.
Apple Inc. · Technology
$337.02
+9.9% upside to fair value
Med Conviction
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+12.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
AAPL |
PFE |
| Current Price |
$337.02 |
$27.64 |
| Fair Value Estimate |
$370.54 |
$30.94 |
| Upside to Fair Value |
+9.9%
|
+12.0%
|
| Market Cap |
$4,949.9B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
29.6x
|
17.4x
|
| Price / Sales |
10.6x
|
2.5x
|
| Price / FCF |
36.2x
|
14.3x
|
| Revenue Growth YoY |
+16.4%
|
+2.6%
|
| Gross Margin |
48.7%
|
71.3%
|
| Operating Margin |
33.2%
|
25.1%
|
| Return on Equity |
137.2%
|
4.9%
|
| Dividend Yield |
0.31% |
6.22% |
| FCF Yield |
2.76%
|
6.97%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Apple Inc. is a global consumer-electronics and services platform whose hardware lineup (iPhone, Mac, iPad, wearables) and digital ecosystem (App Store, Apple Music, iCloud, Apple Pay, advertising) generated $31.78 of revenue per share and $9.30 of free cash flow per share on a trailing basis, with TTM gross margin of 48.7%, operating margin of 33.2%, net margin of 27.6%, and ROE of 137.2%. Busin…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
AAPL |
PFE |
| Zone Low |
$277.91 |
$23.21 |
| Zone High |
$314.96 |
$26.30 |
| In Buy Zone? |
No
|
No
|